Table 1.
Clinical characteristics of patients.
| Microarrays assays | qPCR assays | ELISA assay | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Active UC | Inactive UC | Active UC | Controls | Active UC | |||||
| No. of patients | 8 | 10 | 24 | 6 | 16 | ||||
| Mayo score | MS = 2 | MS = 3 | MS = 0 | MS = 1 | MS = 2 | MS = 3 | MS = 2 | MS = 3 | |
| 7 | 1 | 4 | 6 | 14 | 10 | 7 | 9 | ||
| Female, n (%) | 5 (62.5%) | 5 (50%) | 16 (66%) | 5 (42%) | 8 (50%) | ||||
| Age (y) | |||||||||
| Median | 34 | 46 | 35 | 52.5 | 31.5 | ||||
| Range | 18–44 | 20–76 | 24–60 | 36–70 | 24–53 | ||||
| Duration of IBD (y) | |||||||||
| Median | 3 | 10 | 4 | – | 5.5 | ||||
| Range | 1–7 | 0.6–21 | 0.2–21 | 0.2–21 | |||||
| Treatments | |||||||||
| 5 ASA | 2 | 3 | 5 | 0 | 5 | ||||
| Steroids | 1 | 0 | 3 | 0 | 3 | ||||
| Steroids + 5 ASA | 1 | 0 | 2 | 0 | 2 | ||||
| Steroids + Immunosuppressant | 2 | 0 | 4 | 0 | 4 | ||||
| Steroids + Sulfasalazine | 0 | 1 | 2 | 0 | 2 | ||||
| Sulfasalazine | 0 | 1 | 0 | 0 | 0 | ||||
| 5 ASA + immunosuppressant | 1 | 3 | 0 | 0 | 0 | ||||
| Methotrexate + 5 ASA | 0 | 1 | 0 | 0 | 0 | ||||
| Biologics therapy | |||||||||
| Biologics therapy + 5 ASA + Sulfasalazine | 0 | 1 | 3 | 0 | 0 | ||||
| Biologics therapy + Immunosuppressant | 1 | 0 | 3 | 0 | 0 | ||||
| Biologics therapy + 5 ASA | 0 | 0 | 1 | 0 | 0 | ||||
| Biologics therapy + immunosuppressant + 5 ASA | 0 | 0 | 1 | 0 | 0 | ||||